Comparison of Enerziar and Trelegy, Single inhaler triple therapy (SITT), in asthma

Comparison of Enerziar and Trelegy, Single inhaler triple therapy (SITT), in asthma - Comparison of Enerziar and Trelegy, Single inhaler triple therapy (SITT), in asthma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046368

Enrollment

100

Registered

2021-12-14

Start date

2021-12-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma

Interventions

Enerzair Trelegy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult asthma patients aged 20 years or older with moderate to severe asthma

Exclusion criteria

Exclusion criteria: 1) Patients who have difficulty inhaling by theirself 2) Patients who are unable to perform lung function tests. 3) For example, patients with end-stage cancer, severe heart failure, liver cirrhosis, respiratory failure, etc. 4) Current smokers, pregnant women, under 19 years old

Design outcomes

Primary

Measure	Time frame
QOL scores and forced expiratory volume in 1 second. Background factors of the medication selected as better.	—

Secondary

Measure	Time frame
Various pulmonary function test items, FeNO levels, and frequency of adverse events.	—

Countries

Japan

Contacts

Public ContactMasato Muraki

Kindai University Nara Hospital Department of Respiratory Medicine and Allergology

muraki-m@med.kindai.ac.jp0743-77-0880

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026